194 related articles for article (PubMed ID: 33853571)
1. Prevalence of and factors associated with acute withdrawal symptoms after 24 weeks of eszopiclone treatment in patients with chronic insomnia: a prospective, interventional study.
Inoue Y; Takaesu Y; Koebis M
BMC Psychiatry; 2021 Apr; 21(1):193. PubMed ID: 33853571
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of the Benzodiazepine Hypnotics Withdrawal Symptom Scale (BHWSS) based on item response theory.
Narisawa H; Inoue Y; Kobayashi M; Okajima I; Kikuchi T; Kagimura T; Matsui K; Inada K; Mishima K
Psychiatry Res; 2021 Jun; 300():113900. PubMed ID: 33812220
[TBL] [Abstract][Full Text] [Related]
3. Current state of hypnotic use disorders: Results of a survey using the Japanese version of Benzodiazepine Dependence Self-Report Questionnaire.
Yamamoto M; Inada K; Enomoto M; Habukawa M; Hirose T; Inoue Y; Ishigooka J; Kamei Y; Kitajima T; Miyamoto M; Shinno H; Nishimura K; Ozone M; Takeshima M; Suzuki M; Yamashita H; Mishima K
Neuropsychopharmacol Rep; 2021 Mar; 41(1):14-25. PubMed ID: 33259705
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Suvorexant and Eszopiclone as Alternatives to Benzodiazepines for Treating Insomnia in Patients With Major Depressive Disorder.
Shigetsura Y; Imai S; Endo H; Shimizu Y; Ueda K; Murai T; Itohara K; Nakagawa S; Yonezawa A; Ikemi Y; Fukatsu S; Kitada N; Terada T; Nakagawa T; Matsubara K
Clin Neuropharmacol; 2022 May-Jun 01; 45(3):52-60. PubMed ID: 35579484
[TBL] [Abstract][Full Text] [Related]
5. Cross-validation, predictive validity, and time course of the Benzodiazepine Dependence Self-Report Questionnaire in a benzodiazepine discontinuation trial.
Oude Voshaar RC; Mol AJ; Gorgels WJ; Breteler MH; van Balkom AJ; van de Lisdonk EH; Kan CC; Zitman FG
Compr Psychiatry; 2003; 44(3):247-55. PubMed ID: 12764713
[TBL] [Abstract][Full Text] [Related]
6. Scalability, reliability, and validity of the benzodiazepine dependence self-report questionnaire in outpatient benzodiazepine users.
Kan CC; Breteler MH; Timmermans EA; van der Ven AH; Zitman FG
Compr Psychiatry; 1999; 40(4):283-91. PubMed ID: 10428188
[TBL] [Abstract][Full Text] [Related]
7. Melatonin and melatonin agonists as treatments for benzodiazepines and hypnotics withdrawal in patients with primary insomnia. A systematic review.
Morera-Fumero AL; Fernandez-Lopez L; Abreu-Gonzalez P
Drug Alcohol Depend; 2020 Jul; 212():107994. PubMed ID: 32409111
[TBL] [Abstract][Full Text] [Related]
8. Psychometric properties of the Benzodiazepine Dependence Self-Report Questionnaire - Portuguese Version (BENDEP-SRQ-PV).
Curado DF; Barros VV; Opaleye ES; Noto AR
Trends Psychiatry Psychother; 2020; 42(4):358-367. PubMed ID: 33263708
[TBL] [Abstract][Full Text] [Related]
9. Randomized clinical trial of supervised tapering and cognitive behavior therapy to facilitate benzodiazepine discontinuation in older adults with chronic insomnia.
Morin CM; Bastien C; Guay B; Radouco-Thomas M; Leblanc J; Vallières A
Am J Psychiatry; 2004 Feb; 161(2):332-42. PubMed ID: 14754783
[TBL] [Abstract][Full Text] [Related]
10. Review: Adjunctive pharmacologic approaches for benzodiazepine tapers.
Welsh JW; Tretyak V; McHugh RK; Weiss RD; Bogunovic O
Drug Alcohol Depend; 2018 Aug; 189():96-107. PubMed ID: 29906718
[TBL] [Abstract][Full Text] [Related]
11. Hypnotic discontinuation in chronic insomnia: impact of psychological distress, readiness to change, and self-efficacy.
Belleville G; Morin CM
Health Psychol; 2008 Mar; 27(2):239-48. PubMed ID: 18377143
[TBL] [Abstract][Full Text] [Related]
12. Long-term benzodiazepine and Z-drugs use in England: a survey of general practice [corrected].
Davies J; Rae TC; Montagu L
Br J Gen Pract; 2017 Sep; 67(662):e609-e613. PubMed ID: 28716996
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and associated factors of hypnotics dependence among Japanese outpatients with psychiatric disorders.
Murakoshi A; Takaesu Y; Komada Y; Ishikawa J; Inoue Y
Psychiatry Res; 2015 Dec; 230(3):958-63. PubMed ID: 26614012
[TBL] [Abstract][Full Text] [Related]
14. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations.
Walsh JK; Krystal AD; Amato DA; Rubens R; Caron J; Wessel TC; Schaefer K; Roach J; Wallenstein G; Roth T
Sleep; 2007 Aug; 30(8):959-68. PubMed ID: 17702264
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of discontinuing chronic benzodiazepine use in nursing home residents: a pilot study.
Bourgeois J; Elseviers MM; Van Bortel L; Petrovic M; Vander Stichele RH
Eur J Clin Pharmacol; 2014 Oct; 70(10):1251-60. PubMed ID: 25098683
[TBL] [Abstract][Full Text] [Related]
16. Correlates of benzodiazepine use in individuals with insomnia.
Morin CM; Bélanger L; Bernier F
Sleep Med; 2004 Sep; 5(5):457-62. PubMed ID: 15341890
[TBL] [Abstract][Full Text] [Related]
17. Eszopiclone: its use in the treatment of insomnia.
Monti JM; Pandi-Perumal SR
Neuropsychiatr Dis Treat; 2007 Aug; 3(4):441-53. PubMed ID: 19300573
[TBL] [Abstract][Full Text] [Related]
18. Patient Background Factors Affecting the Therapeutic Outcomes in Response to Eszopiclone in Adult Patients with Chronic Insomnia: A Post Hoc Analysis of a Double-Blind Phase III Study in Japan.
Inoue Y; Kamijo A; Nagai R
J Clin Sleep Med; 2015 Oct; 11(10):1171-8. PubMed ID: 26094929
[TBL] [Abstract][Full Text] [Related]
19. Benzodiazepine tapering: a prospective study.
Vikander B; Koechling UM; Borg S; Tönne U; Hiltunen AJ
Nord J Psychiatry; 2010 Aug; 64(4):273-82. PubMed ID: 20629611
[TBL] [Abstract][Full Text] [Related]
20. Safety of zaleplon in the treatment of insomnia.
Israel AG; Kramer JA
Ann Pharmacother; 2002 May; 36(5):852-9. PubMed ID: 11978165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
